Understand the source comparison
Cartalax for Joint Support: Research Applications Comparison
In Vitro Chondrocyte Culture 1–10 μg/mL in culture media for 48–72 hours COL2A1 mRNA expression, ACAN expression, MMP-13 suppression, proteoglycan secretion BPC-157 shows broader anti-inflammatory effects; Cartalax shows higher specificity for cartilage gene e
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- In Vitro Chondrocyte Culture
- 1–10 μg/mL in culture media for 48–72 hours
- COL2A1 mRNA expression, ACAN expression, MMP-13 suppression, proteoglycan secretion
- BPC-157 shows broader anti-inflammatory effects; Cartalax shows higher specificity for cartilage gene expression
- Best for isolating cartilage-specific transcriptional effects
- Induced Osteoarthritis (Rodent)
- 0.1 mg/kg body weight, subcutaneous, 3× weekly for 6–8 weeks
- Histological cartilage erosion score, Safranin O staining intensity, MMP activity in synovial fluid
- TB-500 demonstrates faster acute repair in ligament/tendon models; Cartalax better for chronic degenerative models
- Ideal for long-term cartilage preservation studies
- Human Observational Trial
- 1 mg daily subcutaneous injection for 10 days, with 90-day follow-up
- WOMAC score reduction, radiographic joint space width, serum CTX-II (cartilage degradation marker)
- Comparable WOMAC improvements to low-dose Thymosin Alpha 1 in inflammation-driven arthritis
- Requires baseline cartilage presence; ineffective in bone-on-bone cases